Introduction {#s1}
============

A growing body of evidence suggest that the onset and the mortality rate of several major cardiovascular events is influenced by seasonal patterns \[[@C1], [@C2]\]. Previous studies reported seasonal trends regarding incidence and/or mortality in acute myocardial infarction (MI) \[[@C3]--[@C6]\], sudden cardiac death \[[@C5], [@C7]\], aortic dissection \[[@C8]\] and stroke \[[@C9]\]. For MI, studies revealed that both, the incidence \[[@C3], [@C10], [@C11]\] as well as the short-term mortality \[[@C3], [@C4]\] of an acute MI event were higher in cold winter months than in warm summer months. In addition, the role of temperature has also been explored \[[@C3], [@C10], [@C12]\].

For the life-threatening cardiovascular event of an acute pulmonary embolism (PE) the existence of seasonal variability has been debated for years and results on sex-specific differences regarding these variations are sparse \[[@C2]\]. Published studies investigating seasonal variations of incidence and mortality of PE showed inconsistent results \[[@C1], [@C2], [@C13]--[@C23]\]. While some studies identified seasonal variations \[[@C1], [@C2], [@C13], [@C15], [@C16], [@C18]--[@C21], [@C23]\], others did not \[[@C14], [@C17]\].

Thus, the objectives of the present study were 1) to investigate seasonal variation of incidence and in-hospital mortality of patients with an acute PE; 2) identify seasonal differences regarding age, sex, comorbidities, risk stratification markers and usage of reperfusion treatments; and 3) to detect sex-specific and age-related differences regarding seasonal variations in the large German nationwide inpatient sample.

Methods {#s2}
=======

Data source {#s2a}
-----------

The German Research Data Center (RDC) of the Federal Statistical Office and the Statistical Offices of the federal states (source: RDC of the Federal Statistical Office and the Statistical Offices of the Federal States, DRG Statistics 2005--2015, own calculations) in Wiesbaden (Germany) analysed the data on our behalf and provided aggregated statistic results on the basis of SPSS syntaxes (SPSS^®^ software, version 20.0, SPSS Inc., Chicago, IL, USA), which we had supplied to the RDC.

Diagnoses, procedural codes, and definitions {#s2b}
--------------------------------------------

Diagnoses were coded according to the International Classification of Diseases and Related Health Problems in its 10th Revision with German Modification (ICD-10-GM) and diagnostic, surgical or interventional procedures were coded according to the German Procedure Classification (OPS, surgery, diagnostic and procedures codes; Operationen und Prozedurenschlüssel).

Hospitalised patients diagnosed with PE (ICD code I26) between 2005 and 2015 were included in this analysis. PE patients were stratified according to seasons and patients admitted in the seasons summer and winter were compared. Seasons were defined as: winter included the months December to February, spring included March to May, summer included June to August and autumn included September to November.

Monthly mean temperature in Germany was obtained by the German meteorological service (Deutscher Wetterdienst).

Study outcome {#s2c}
-------------

The primary study outcome was all-cause in-hospital death.

Ethical aspects {#s2d}
---------------

As this study did not involve direct access by the investigators to data of individual patients, approval by an ethics committee and informed consent were not required, in accordance with German law.

### Statistical methods {#s2d1}

Annual total numbers of hospitalisations for acute PE and incidence of acute PE were calculated. In addition, in-hospital mortality rate was computed.

Descriptive statistics for relevant baseline comparisons and outcomes of hospitalisations of PE patients in the different seasons were presented and hospitalisations of the winter and summer seasons (presumed maximum and nadir of temperature difference and incidence) were compared. We tested the continuous variables using the Mann--Whitney U-test and categorical variables with chi-squared test or Fisher\'s exact test, as appropriate.

Seasonal variation was additionally tested by ANOVA to compare the PE cases in the different seasons. If it was significant (*i.e.* p\<0.05), then the Tukey *post hoc* test was used for *post hoc* comparison of multiple means to determine which seasons were significantly different.

Univariate and multivariate logistic regression models were analysed to investigate the impact of season (winter *versus* summer season) on in-hospital mortality, cardiopulmonary resuscitation (CPR), the presentation with haemodynamically instability (defined as shock and/or CPR), right ventricular (RV) dysfunction, tachycardia, syncope, bleeding events and reperfusion treatments. The results were presented as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Multivariate logistic regression models included the following parameters for adjustment: Adjustment I: age, sex, active cancer (ICD codes C00-C97), heart failure (ICD code I50), chronic obstructive pulmonary disease (COPD, ICD code J44), essential arterial hypertension (ICD-code I10), acute and chronic kidney disease (ICD-codes N17-N19), diabetes mellitus (ICD-codes E10-E14), obesity, and coronary artery disease (ICD-code I25).Adjustment II: for sex-specific analysis adjustment I was used without the variable sex.Adjustment III: variables of adjustment I with further variables: RV dysfunction (ICD-code I26.0), tachycardia (ICD-code I47), syncope (ICD-code R55) and haemodynamically unstable PE (PE with additional shock or CPR).Adjustment IV: for additional sex-specific analysis adjustment III was used without the variable sex.The software SPSS^®^ (versions 20.0 and 23.0; SPSS Inc., Chicago, IL, USA) was used for computerised analysis. P-values of \<0.05 (two-sided) were considered to be statistically significant.

Results {#s3}
=======

Total numbers of pulmonary embolism and mortality rate (2005--2015) {#s3a}
-------------------------------------------------------------------

During a time period of 11 years (from 2005 to 2015), the German nationwide sample included 885 806 hospitalised patients with PE. Of those, 147 234 (16.6%) died during in-hospital stay.

Patient characteristics stratified by seasons {#s3b}
---------------------------------------------

The patient characteristics stratified by seasons revealed a higher quarterly annual incidence of PE during winter compared to the summer (25.5 *versus* 23.7 hospitalisations per 100 000 population, p=0.021). In parallel, highest mortality and CPR rates were found in winter and spring and lowest in summer and autumn ([table 1](#TB1){ref-type="table"}, [figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Patients hospitalised in winter were more often older than 70 years and of female sex in comparison to patients hospitalised in summer. Additionally, patients hospitalised in the summer were more often obese, presented less with diabetes mellitus and suffered more often from heart failure and cancer in comparison to patients hospitalised in winter ([table 1](#TB1){ref-type="table"}).

###### 

Patient characteristics of 885 806 hospitalisations with acute pulmonary embolism (PE) stratified by seasons

                                                     **Winter**          **Spring**          **Summer**          **Autumn**          **p-value for difference between summer and winter**
  -------------------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------------------------------------------
  **Temperature**                                                                                                                    
   Median temperature^\#^ in Germany                 1.1 (−0.5--3.6)     8.7 (5.7--12.4)     17.2 (16.1--18.2)   9.1 (6.8--12.8)     **\<0.001**
  **Incidence, total numbers and length of stay**                                                                                    
   3-month incidence of PE per 100 000 citizens      25.5                24.1                23.7                25.3                **0.021**
   Number of PE events                               229 379 (25.9%)     216 420 (24.4%)     212 595 (24.0%)     227 412 (25.7%)     **0.021**
   In-hospital stay days                             10 (6--16)          10 (6--17)          10 (6--16)          10 (6--16)          **0.001**
  **Patients\' characteristics and comorbidities**                                                                                   
   Age at event years                                72.0 (61.0--80.0)   72.0 (61.0--80.0)   72.0 (60.0--80.0)   72.0 (60.0--80.0)   **\<0.001**
   Age \>70 years                                    124 578 (54.3%)     117 899 (54.5%)     114 166 (53.7%)     122 950 (54.1%)     **\<0.001**
   Female sex (n=885 770)                            124 150 (54.1%)     117 827 (54.4%)     113 473 (53.4%)     123 428 (54.3%)     **\<0.001**
   Obesity^¶^                                        21 224 (9.3%)       20 936 (9.7%)       21 162 (10.0%)      21 961 (9.7%)       **\<0.001**
   Diabetes mellitus                                 42 018 (18.3%)      40 781 (18.8%)      40 720 (19.2%)      42 233 (18.6%)      **\<0.001**
   Hyperlipidaemia                                   25 882 (11.3%)      24 649 (11.4%)      24 472 (11.5%)      27 035 (11.9%)      **0.017**
   Essential arterial hypertension                   96 860 (42.2%)      91 899 (42.5%)      89 806 (42.2%)      97 545 (42.9%)      0.916
   Coronary artery disease                           31 183 (13.6%)      30 406 (14.0%)      29 801 (14.0%)      31 448 (13.8%)      **\<0.001**
   Heart failure                                     47 476 (20.7%)      46 496 (21.5%)      45 372 (21.3%)      47 783 (21.0%)      **\<0.001**
   Atrial fibrillation/flutter                       35 256 (15.4%)      34 420 (15.9%)      33 288 (15.7%)      34 647 (15.2%)      **0.008**
   Cancer                                            43 596 (19.0%)      43 227 (20.0%)      44 066 (20.7%)      45 344 (19.9%)      **\<0.001**
   COPD                                              24 313 (10.6%)      23 513 (10.9%)      21 756 (10.2%)      23 076 (10.1%)      **\<0.001**
   Stroke                                            6099 (2.7%)         5887 (2.7%)         5921 (2.8%)         5909 (2.6%)         **0.010**
   Acute and chronic kidney disease                  44 862 (19.6%)      43 408 (20.1%)      43 633 (20.5%)      45 340 (19.9%)      **\<0.001**
  **Bleeding events during hospitalisation**                                                                                         
   Gastro-intestinal bleeding                        3127 (1.4%)         2939 (1.4%)         2961 (1.4%)         3120 (1.4%)         0.400
   Subarachnoid bleeding                             305 (0.1%)          318 (0.1%)          354 (0.2%)          341 (0.1%)          **0.004**
   Intracerebral bleeding                            1274 (0.6%)         1273 (0.6%)         1265 (0.6%)         1248 (0.5%)         0.082
   Transfusion of erythrocyte concentrates           25 428 (11.1%)      25 681 (11.9%)      26 432 (12.4%)      26 286 (11.6%)      **\<0.001**
  **Reperfusion treatments**                                                                                                         
   Surgical embolectomy                              351 (0.2%)          322 (0.1%)          346 (0.2%)          375 (0.2%)          0.415
   Systemic thrombolysis                             9791 (4.3%)         8858 (4.1%)         8812 (4.1%)         9456 (4.2%)         **0.041**
  **Risk stratification and deep vein thrombosis**                                                                                   
   Deep vein thrombosis or thrombophlebitis          83 757 (36.5%)      76 093 (35.2%)      75 469 (35.5%)      82 669 (36.4%)      **\<0.001**
   Tachycardia                                       4099 (1.8%)         3947 (1.8%)         4038 (1.9%)         4211 (1.9%)         **0.005**
   Syncope                                           5459 (2.4%)         5057 (2.3%)         5006 (2.4%)         5356 (2.4%)         0.582
   Haemodynamic instability                          20 549 (9.0%)       19 478 (9.0%)       19 032 (9.0%)       19 584 (8.6%)       0.942
   Shock                                             7848 (3.4%)         7668 (3.5%)         7582 (3.6%)         7841 (3.4%)         **0.009**
  **Primary outcome**                                                                                                                
   CPR                                               15 949 (7.0%)       15 002 (6.9%)       14 486 (6.8%)       15 082 (6.6%)       0.068
   In-hospital death                                 38 921 (17.0%)      37 115 (17.1%)      35 439 (16.7%)      35 759 (15.7%)      **0.008**

Data are presented as n (%) or median (interquartile range), unless otherwise stated. CPR: cardiopulmonary resuscitation. ^\#^: Median temperature in the different seasons during the observational timeframe (2005--2015); ^¶^: Obesity was defined according to the World Health Organization (body mass index ≥30 kg·m^−2^). Bold text indicates p\<0.05.

![a) Absolute numbers of pulmonary embolism (PE) (bars) and in-hospital mortality rate (line) stratified for seasons in the years 2005--2015. b) Absolute numbers of PE (bars) and in-hospital mortality rate (line) stratified by seasons (cumulative 2005--2015).](00181-2020.01){#F1}

![Time trend of absolute numbers of pulmonary embolism (PE) (bars) and in-hospital mortality rate (line) stratified for months from 2005--2015.](00181-2020.02){#F2}

Seasonal variation of PE incidence {#s3c}
----------------------------------

The ANOVA confirmed that the seasonal variation regarding incidence of PE was of substantial magnitude (p=0.021) ([table 1](#TB1){ref-type="table"}). PE incidence differed between winter and summer, but not between other seasons ([figure 1](#F1){ref-type="fig"}). Regarding in-hospital mortality, the summer season was significantly different from winter, spring and autumn. In addition, seasonal variations between autumn and winter as well as between autumn and spring were significant ([figure 1](#F1){ref-type="fig"}, [table 2](#TB2){ref-type="table"}). In the logistic regression analysis, incidence of PE in winter was higher than in summer months (OR 1.85 (95% CI 1.09--3.13), p=0.022).

###### 

Results of the significance level computed with the Tukey *post hoc* test (ANOVA analysis) regarding in-hospital mortality differences between the different seasons

  **All patients**      **Winter**                     **Spring**    **Summer**                     **Autumn**                                                                                
  --------------------- ------------------------------ ------------- ------------------------------ ------------- ------------------------------ ------------- ------------------------------ -------------
  **Winter**                                                         −0.002 (−0.005--0.002)         0.363         0.003 (0.000--0.006)           **0.039**     0.012 (0.010--0.015)           **\<0.001**
  **Spring**            0.002 (−0.002--0.005)          0.363                                                      0.005 (0.002--0.008)           **0.0001**    0.014 (0.011--0.017)           **\<0.001**
  **Summer**            −0003 (−0.006-- −0.000)        **0.039**     −0.005 (−0.008--0.002)         **0.0001**                                                 0.009 (0.007--0.012)           **\<0.001**
  **Autumn**            −0.012 (−0.015-- −0.010)       **\<0.001**   −0.014 (−0.017-- −0.011)       **\<0.001**   −0.009 (−0.012-- −0.007)       **\<0.001**                                  
  **Male patients**     **Winter**                     **Spring**    **Summer**                     **Autumn**                                                                                
                        **Mean difference (95% CI)**   **p-value**   **Mean difference (95% CI)**   **p-value**   **Mean difference (95% CI)**   **p-value**   **Mean difference (95% CI)**   **p-value**
  **Winter**                                                         −0.06 (−0.010 to −0.002)       **0.003**     0.002 (−0.002 to 0.007)        0.483         0.008 (0.004 to 0.012)         **\<0.001**
  **Spring**            0.006 (0.002 to 0.010)         **0.003**                                                  0.008 (0.004 to 0.012)         **\<0.001**   0.014 (0.010 to 0.018)         **\<0.001**
  **Summer**            −0.002 (−0.007 to 0.002)       0.483         −0.008 (−0.012 to −0.004)      **\<0.001**                                                0.006 (0.002 to 0.010)         **0.002**
  **Autumn**            −0.008 (−0.012 to −0.004)      **\<0.001**   −0.014 (−0.018 to −0.010)      **\<0.001**   −0.006 (−0.010 to −0.002)      **0.002**                                    
  **Female patients**   **Winter**                     **Spring**    **Summer**                     **Autumn**                                                                                
                        **Mean difference (95% CI)**   **p-value**   **Mean difference (95% CI)**   **p-value**   **Mean difference (95% CI)**   **p-value**   **Mean difference (95% CI)**   **p-value**
  **Winter**                                                         0.001 (−0.002--0.005)          0.760         0.003 (−0.001--0.007)          0.106         0.160 (0.012--0.020)           **\<0.001**
  **Spring**            −0.001 (−0.005--0.002)         0.760                                                      0.002 (−0.002--0.006)          0.577         0.015 (0.011--0.018)           **\<0.001**
  **Summer**            −0.003 (−0.007--0.005)         0.106         −0.002 (−0.006--0.002)         0.577                                                      0.013 (0.009--0.017)           **\<0.001**
  **Autumn**            −0.016 (−0.020-- −0.012)       **\<0.001**   −0.015 (−0.018-- −0.011)       **\<0.001**   −0.013 (−0.017-- −0.009)       **\<0.001**                                  

Age-dependent analysis demonstrated that a winter peak and summer nadir was identified in patients aged 60 years and older, but not in younger PE patients ([figure 3a](#F3){ref-type="fig"}).

![a) Seasonal proportion of numbers of pulmonary embolism (PE) (cumulative 2005--2015) in the different age-decades (sum of seasonal percentages in each age-decade is 100%). b) Seasonal proportion of deaths (cumulative 2005--2015) in the different age-decades (sum of seasonal percentages in each age-decade is 100%).](00181-2020.03){#F3}

Seasonal differences in risk stratification of PE {#s3d}
-------------------------------------------------

Rates of PE with haemodynamic instability and syncope were comparable between different seasons ([table 1](#TB1){ref-type="table"}). In contrast, tachycardia was more often found in the summer season. The logistic regressions revealed that RV dysfunction occurred more often in the winter months than in the summer independently of age, sex and comorbidities ([table 3](#TB3){ref-type="table"}).

###### 

Impact of winter season on different clinical parameters and outcomes in comparison to summer season

  **All PE patients (sex-unspecific analyses)**   **Univariate analysis OR (95% CI)**   **p-value**   **Multivariate analysis^\#^** **OR (95% CI)**   **p-value**
  ----------------------------------------------- ------------------------------------- ------------- ----------------------------------------------- -------------
  **Reperfusion treatment**                                                                                                                           
   Surgical pulmonary embolectomy                 0.94 (0.81--1.09)                     0.415         1.00 (0.86--1.16)                               0.950
   Systemic thrombolysis                          1.03 (1.00--1.06)                     **0.041**     1.04 (1.01--1.07)                               **0.008**
  **Risk stratification**                                                                                                                             
   Haemodynamically unstable PE                   1.01 (0.98--1.02)                     0.942         1.01 (0.99--1.03)                               0.238
   Right ventricular dysfunction                  1.04 (1.03--1.06)                     **\<0.001**   1.04 (1.03--1.06)                               **\<0.001**
   Tachycardia                                    0.94 (0.90--0.98)                     **0.005**     0.96 (0.91--1.00)                               **0.041**
   Syncope                                        1.01 (0.97--1.05)                     0.582         1.00 (0.96--1.04)                               0.955
  **In-hospital outcomes**                                                                                                                            
   CPR                                            1.02 (1.00--1.05)                     0.068         1.03 (1.01--1.05)                               **0.017**
   In-hospital death                              1.02 (1.01--1.04)                     **0.008**     1.04 (1.02--1.05)                               **\<0.001**
  **Intra-hospital bleeding events**                                                                                                                  
   Gastro-intestinal bleeding                     0.98 (0.93--1.03)                     0.400         0.97 (0.95--1.05)                               0.869
   Subarachnoid bleeding                          0.80 (0.69--0.93)                     **0.004**     0.80 (0.69--0.93)                               **0.005**
   Intracerebral bleeding                         0.93 (0.86--1.01)                     0.082         0.93 (0.86--1.01)                               0.073
  **Men**                                         **Univariate OR (95% CI)**            **p-value**   **Multivariate^¶^ OR (95% CI)**                 **p-value**
  **Reperfusion treatment**                                                                                                                           
   Surgical pulmonary embolectomy                 0.94 (0.77--1.15)                     0.524         1.00 (0.82--1.22)                               0.973
   Systemic thrombolysis                          1.06 (1.01--1.10)                     **0.011**     1.07 (1.03--1.12)                               **0.002**
  **Risk stratification**                                                                                                                             
   Haemodynamically unstable PE                   0.99 (0.96--1.02)                     0.424         1.00 (0.97--1.03)                               0.936
   Right ventricular dysfunction                  1.05 (1.03--1.07)                     **\<0.001**   1.05 (1.03--1.07)                               **\<0.001**
   Tachycardia                                    0.93 (0.88--1.00)                     **0.036**     0.95 (0.89--1.02)                               0.145
   Syncope                                        1.00 (0.95--1.07)                     0.901         0.99 (0.94--1.05)                               0.821
  **In-hospital outcomes**                                                                                                                            
   CPR                                            1.00 (0.97--1.04)                     0.803         1.01 (0.98--1.05)                               0.483
   In-hospital death                              1.02 (0.99--1.04)                     0.154         1.03 (1.01--1.06)                               **0.015**
  **Intra-hospital bleeding events**                                                                                                                  
   Gastro-intestinal bleeding                     0.95 (0.88--1.02)                     0.185         0.97 (0.90--1.04)                               0.406
   Subarachnoid bleeding                          0.94 (0.75--1.17)                     0.565         0.94 (0.75--1.19)                               0.619
   Intracerebral bleeding                         1.02 (0.91--1.13)                     0.785         1.01 (0.91--1.13)                               0.829
  **Women**                                       **Univariate OR (95% CI)**            **p-value**   **Multivariate^¶^ OR (95% CI)**                 **p-value**
  **Reperfusion treatment**                                                                                                                           
   Surgical pulmonary embolectomy                 0.95 (0.76--1.19)                     0.647         1.00 (0.80--1.24)                               0.978
   Systemic thrombolysis                          1.01 (0.97--1.05)                     0.666         1.01 (0.97--1.06)                               0.522
  **Risk stratification**                                                                                                                             
   Haemodynamically unstable PE                   1.01 (0.99--1.04)                     0.332         1.02 (0.99--1.05)                               0.117
   Right ventricular dysfunction                  1.04 (1.02--1.05)                     **\<0.001**   1.03 (1.02--1.05)                               **\<0.001**
   Tachycardia                                    0.95 (0.89--1.00)                     0.068         0.96 (0.90--1.02)                               0.153
   Syncope                                        1.01 (0.96--1.07)                     0.592         1.01 (0.96--1.06)                               0.812
  **In-hospital outcomes**                                                                                                                            
   CPR                                            1.04 (1.01--1.08)                     **0.016**     1.05 (1.01--1.08)                               **0.008**
   In-hospital death                              1.03 (1.00--1.05)                     **0.025**     1.04 (1.02--1.06)                               **0.001**
  **Intra-hospital bleeding events**                                                                                                                  
   Gastro-intestinal bleeding                     1.00 (0.94--1.08)                     0.918         1.02 (0.95--1.09)                               0.566
   Subarachnoid bleeding                          0.70 (0.57--0.86)                     **0.001**     0.70 (0.57--0.86)                               **0.001**
   Intracerebral bleeding                         0.85 (0.76--0.96)                     **0.006**     0.85 (0.76--0.95)                               **0.004**

PE: pulmonary embolism; CPR: cardiopulmonary resuscitation. ^\#^: Adjustment I; ^¶^: Adjustment II.

Seasonal differences in reperfusion treatments {#s3e}
----------------------------------------------

While surgical embolectomy was performed in all seasons in similar frequency, systemic thrombolysis was more often used in winter ([table 1](#TB1){ref-type="table"}). The logistic regression analysis confirmed a higher use of the reperfusion treatment systemic thrombolysis in the winter months independently of age, sex and comorbidities ([table 3](#TB3){ref-type="table"}).

Seasonal variation of PE patients\' in-hospital mortality rate {#s3f}
--------------------------------------------------------------

Similarly, seasonal variation regarding PE patients\' in-hospital mortality was also of substantial magnitude (p\<0.001) ([table 3](#TB3){ref-type="table"}). The regression models confirmed that winter was associated with an increased risk of mortality (OR 1.04 (95% CI 1.02--1.05), p\<0.001) independently of age, sex and comorbidities (adjustment I) in comparison to the summer ([table 3](#TB3){ref-type="table"}). This result remains stable after further adjustment for risk stratification markers (adjustment III) (OR 1.03 (95% CI 1.01--1.05), p=0.001).

Winter was related to higher mortality in male and female independently of age and comorbidities (adjustment II) (male: OR 1.03 (95% CI 1.01--1.06), p=0.015; female: OR 1.04 (95% CI 1.02--1.06), p=0.001) ([table 3](#TB3){ref-type="table"}) in comparison to summer season. These results remained significant after further adjustment for risk stratification markers (adjustment IV) (men: OR 1.03 (95% CI 1.00--1.06), p=0.048; women: OR 1.04 (95% CI 1.01--1.06), p=0.010). However, we detected some sex-specific differences regarding seasonal variation of incidence and in-hospital mortality ([figure 3](#F3){ref-type="fig"}). In males and females, the highest quarterly annual incidence of PE was observed during winter, whereas the lowest hospitalisation rate of male patients was found in spring and of female patients in summer. Both sexes showed a maximum of in-hospital mortality in the spring ([figure 4](#F4){ref-type="fig"}).

![Absolute numbers of PE events (bars) and in-hospital mortality rate (line) stratified by seasons in a) female and b) male patients (cumulative 2005--2015).](00181-2020.04){#F4}

Age-dependent analysis showed, that PE patients in their third decade and older revealed a winter peak in the in-hospital mortality ([figure 3b](#F3){ref-type="fig"}).

Discussion {#s4}
==========

PE is a major cause of morbidity and mortality worldwide \[[@C13], [@C24], [@C25]\]. Seasonal variation for incidence and mortality of PE is still debated \[[@C2]\]. Only a limited number of studies investigated seasonal variations of incidence and mortality in PE patients and the results were not consistent \[[@C1], [@C2], [@C13]--[@C23]\]. The German nationwide inpatient sample enabled us to investigate the seasonal variations regarding incidence and in-hospital mortality of PE in more than 885 000 patients. In addition, and of importance we could identify differences in age, sex, comorbidities, risk stratification markers and usage of reperfusion treatments, which might explain, even in part, the seasonal variations.

Key findings of our study are summarised as follows: 1)Incidence and in-hospital mortality rate of hospitalised PE patients showed a significant seasonal variation.2)Highest incidence of PE was during winter and lowest in summer.3)Highest in-hospital mortality rate of PE was observed in winter and spring, whereas in-hospital mortality was lowest in summer and autumn.4)Seasonal variation regarding the in-hospital mortality rate revealed some sex-specific differences, but differences between summer and winter were identified in both sexes independently of age, comorbidities and risk stratification markers.5)Seasonal variation regarding PE incidence and mortality was pronounced in older patients.Germany is located in the temperate climate zone of western Europe with annual mean temperatures between 8 and 9°C. The weather is characterised by four distinct seasons with a striking contrast between winter and summer: lowest mean temperatures were measured in January (winter, approximately −0.5 to 0.5°C) and highest in July (summer, approximately 17--18°C). The median cumulative seasonal temperatures in the timeframe between 2005 and 2015 are shown in [table 1](#TB1){ref-type="table"}.

We identified in this German inpatient sample a significant seasonal variation regarding incidence and in-hospital mortality.

Seasonal difference regarding the incidence of acute PE {#s4a}
-------------------------------------------------------

In accordance with most studies about seasonal variation in PE \[[@C2], [@C15], [@C19]--[@C22]\], the highest PE incidence in Germany was observed in the winter months. A winter peak was also demonstrated in three large studies with respectively more than 160 000 patients analysing nationwide samples of England, France and Spain \[[@C2], [@C19], [@C20]\]. In contrast, smaller studies showed peaks of incidence in autumn \[[@C23]\] and spring \[[@C18]\]. In addition, S[tein]{.smallcaps} *et al*. \[[@C17]\] published the largest study with 2 457 000 PE cases of the National Hospital Discharge Survey of the United States of America without a confirmation of a seasonal variation regarding quarterly annual PE incidence. This country-specific difference between smaller countries such as Germany and large countries such as the United States of America might be driven by climate diversity. While Germany has only the temperate climate of mid-western Europe, the United States of America comprise different climate zones.

Furthermore, studies suggested an age-dependent impact on seasonal variation of PE incidence with an increase in older individuals, especially in those older than 50 years \[[@C16], [@C19]\]. These results were confirmed by our study, showing the typically peak regarding the incidence in winter and the nadir in summer for patients in the 7th life-decade and older.

Seasonal differences regarding in-hospital mortality rate {#s4b}
---------------------------------------------------------

In Germany, the highest in-hospital mortality rate of acute PE was observed in winter and spring, whereas a lowest in-hospital rate was found during summer and autumn. Remarkably, seasonal variation regarding the in-hospital mortality rate revealed some sex-specific differences, but the differences between summer and winter were identified in both sexes independently of age, comorbidities and risk stratification markers. Only a few studies have investigated a seasonal variation of short-term mortality, with inconsistent results \[[@C13], [@C14], [@C18], [@C19]\]. While two studies reported a winter peak \[[@C14], [@C19]\], one study could not confirm any seasonal variation \[[@C18]\] and another one described two peaks in spring and autumn \[[@C13]\]. The largest study investigating seasonal variation of in-hospital death investigated 599 432 PE patients and demonstrated an increase of 25% of mortality in winter compared to summer \[[@C19]\]. Although our study results are in accordance with the findings of O[lie]{.smallcaps} *et al*. \[[@C19]\], we detected only a 9% increase of in-hospital mortality in the winter season in comparison to summer. Interestingly, seasonal variation was identified for all patients of the third life-decade and older.

Although potential aetiologies for seasonal patterns are not well understood \[[@C3], [@C11]\], a number of pathophysiological factors might contribute to the seasonal variation regarding incidence and in-hospital mortality of patients with acute PE \[[@C22], [@C26]\]. As mentioned for Germany above, most countries with seasonal variation show a significant seasonal change in ambient temperature \[[@C22], [@C23]\]. Thus, most authors suggest that the temperature is an important factor causing seasonal pattering of cardiovascular mortality \[[@C1], [@C13], [@C22], [@C26]\]. Consecutively, studies demonstrated that cold weather with 1°C decrease in air temperature was associated with an excess of deaths for up to a month \[[@C1], [@C21], [@C22]\]. In addition, the wind-chill temperature should also be taken in account as it influences short-term mortality \[[@C1], [@C21], [@C22], [@C27]\]. Environmental temperature has an influence on the onset of acute PE, which is most likely multifactorial \[[@C1], [@C22], [@C26]\]. It has been proposed that temperature and the resulting variation in biological factors mediate seasonal differences \[[@C11], [@C21]\]. Pathophysiologically, even mild surface cooling of the skin and the tissues beneath the skin including the vessels produces an increased blood viscosity and changes in coagulation \[[@C1], [@C2], [@C21]--[@C23], [@C26]\]. Hypercoagulable states could be promoted by elevated fibrinogen levels, which increase in colder months \[[@C1], [@C19], [@C21]--[@C23]\]. Moreover, studies confirmed a correlation between air pressure and humidity with the occurrence of PE \[[@C22], [@C28]\]. Physical activity is dramatically reduced due to colder temperatures especially in older individuals, which favours prothrombotic changes \[[@C1], [@C2], [@C15], [@C19], [@C22], [@C23]\]. Respiratory infections such as bronchitis, pneumonia and acute exacerbation of COPD are more prevalent in the winter months and accompanied by inflammatory states, which could contribute to development of venous thromboembolism \[[@C15], [@C19], [@C29]--[@C32]\]. In summary, it has to be hypothesised that changes in coagulation system, inflammation/infections, comorbidities as well as peripheral vasoconstrictions with reduction of blood flow in the legs increase the risk of deep vein thrombosis and PE in the winter seasons \[[@C15], [@C22], [@C26]\]. Another explanation focuses on air pollution \[[@C21], [@C26]\]. Air pollution seems to have an effect on pulmonary diseases, the coagulation system and on platelet function \[[@C26], [@C31], [@C33], [@C34]\]. Air pollutants are elevated predominantly in the colder season of winter and might therefore contribute to the seasonal variation and the higher incidence of acute cardiovascular events such as deep vein thrombosis and PE \[[@C19], [@C26], [@C32], [@C33], [@C35], [@C36]\].

In studies about seasonal variation in MI patients, it was presumed that the higher mortality rate during the winter was attributed to a higher number of comorbidities \[[@C3], [@C11]\] as well as an increased age of the MI patients during winter months \[[@C4]\]. Our study confirmed a higher proportion of PE patients aged \>70 years during the winter in comparison to summer season, but not an accumulation of important comorbidities in the winter season, which is in accordance with the study of M[anfredini]{.smallcaps} *et al*. \[[@C1]\]. However, in our multivariate logistic regression analyses, the independence of seasonal variation of in-hospital mortality regarding age, sex and important comorbidities was demonstrated. Thus, we could reject the presumed explanations of seasonal mortality variation with respect to age and the investigated comorbidities.

N[agarajan]{.smallcaps} *et al*. \[[@C37]\] identified some seasonal treatment variations in MI patients admitted for acute MI in summer and winter seasons. Patients admitted in summer revealed a significant shorter door to balloon time than in the winter \[[@C37]\]. In contrast, our study results revealed no lower reperfusion treatment rates in PE patients admitted in the winter.

Interestingly, our study results identified a higher rate of RV dysfunction in the winter season. RV dysfunction and signs of haemodynamic compromise are important risk stratification tools in acute PE and associated with an increased mortality \[[@C24], [@C38]\]. Although the cause of the higher rate of RV dysfunction in the winter seasons remains unclear, this finding might explain in part the higher mortality rate of PE in the winter months compared to the summer. Colder weather is further accompanied by an increase in sympathetic tone, heart rate, blood pressure, atrial spasm, myocardial oxygen consumption, haematocrit, granulocyte count, cortisol level, serum cholesterol and triglyceride levels, red blood cell and platelet count, plasma β-thromboglobulin, platelet factor 4, activated factor VII and plasma fibrinogen, whereas anti-thrombin III decreases with colder temperatures \[[@C3], [@C6], [@C10], [@C11]\]. Therefore, the higher rate of RV dysfunction might be attributed especially to the elevated myocardial oxygen consumption in the winter season accompanied with an increased risk of cardiac adaptations (RV dysfunction).

In accordance with the study of Z[öller]{.smallcaps} *et al*. \[[@C16]\], we found a weak sex-specific difference regarding the seasonal variation in PE patients. We detected especially differences in the seasonal variation of the in-hospital mortality of male and female PE patients. In male patients, seasonal differences between spring and summer as well as spring and winter were demonstrated, whereas female patients did not have these seasonal differences between spring and the other seasons ([table 3](#TB3){ref-type="table"}). An explanation for this finding was not obvious.

Adequate management of public health as well as healthcare service planning requires reliable information about temporal/seasonal variation regarding hospitalisations and adverse events due to common diseases \[[@C39]\]. Thus, our results regarding seasonal variation are important to allow prospective healthcare planning and management \[[@C39]\]. Seasonal trends regarding heart and lung diseases should not be underestimated, because these diseases have a high prevalence in Germany and the world. The adequate planning of healthcare resources is of particular interest to avoid the negative effects of a shortage of resources.

### Limitations {#s4b1}

There are certain limitations of our study that require consideration. First, study results were based on ICD discharge codes, which might be subject to underreporting or miscoding. Second, detailed baseline data such as concomitant medications, cardiac troponin plasma concentrations, and echocardiographic parameters were not available. Therefore, the focus of our study was on the clear end-point of in-hospital death.

Conclusions {#s5}
===========

The incidence and in-hospital mortality rate of hospitalised PE patients showed seasonal variation. Although it has to be hypothesised that the seasonal variation of PE is multifactorially induced, seasonal variation was not explained by seasonal differences regarding age, sex and important comorbidities. In addition, sex-specific differences of seasonal variation regarding PE were observed.
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